Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
$1.83
+2.8%
$1.64
$1.33
$2.89
$54.11M1.85406,060 shs195,438 shs
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
$0.53
-4.1%
$0.44
$0.27
$1.18
$24.44M-0.052.11 million shs346,759 shs
Longeveron Inc. stock logo
LGVN
Longeveron
$1.34
-0.7%
$1.49
$0.77
$6.40
$20.00M0.382.96 million shs89,961 shs
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
$16.05
-9.6%
$19.26
$12.12
$27.50
$51.20M0.7723,384 shs10,710 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
+2.81%+4.57%+11.59%+14.38%-2.14%
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
-4.15%+8.96%+18.67%+49.50%-51.89%
Longeveron Inc. stock logo
LGVN
Longeveron
-0.74%0.00%-23.43%-11.26%+21.82%
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
-9.63%-22.65%-28.84%-11.15%-42.10%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
2.1393 of 5 stars
3.50.00.00.02.83.30.6
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
2.8706 of 5 stars
3.55.00.00.02.40.01.3
Longeveron Inc. stock logo
LGVN
Longeveron
3.341 of 5 stars
3.65.00.00.02.11.71.3
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
2.1955 of 5 stars
3.55.00.00.02.60.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
3.00
Buy$21.001,047.54% Upside
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
3.00
Buy$4.00649.06% Upside
Longeveron Inc. stock logo
LGVN
Longeveron
3.25
Buy$8.67546.77% Upside
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
3.00
Buy$35.50121.18% Upside

Current Analyst Ratings Breakdown

Latest LGVN, FBIO, VTVT, and IPA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/11/2025
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
4/9/2025
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$36.00
4/1/2025
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSpeculative Buy ➝ Speculative Buy$3.00 ➝ $3.00
3/31/2025
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$7.00 ➝ $5.00
3/21/2025
Longeveron Inc. stock logo
LGVN
Longeveron
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
3/14/2025
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
3/11/2025
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
Roth Mkm
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00 ➝ $16.00
3/3/2025
Longeveron Inc. stock logo
LGVN
Longeveron
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
$57.78M0.94N/AN/A$0.10 per share18.30
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
$24.00M1.02N/AN/A$0.93 per share0.57
Longeveron Inc. stock logo
LGVN
Longeveron
$2.23M8.99N/AN/A$2.68 per share0.50
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
$17K3,011.74N/AN/A($9.27) per share-1.73
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
-$60.64M-$2.23N/AN/AN/A-84.53%N/A-34.93%8/12/2025 (Estimated)
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
-$20.13M-$1.16N/AN/AN/A-114.50%-73.74%-42.68%8/4/2025 (Estimated)
Longeveron Inc. stock logo
LGVN
Longeveron
-$21.41M-$6.28N/AN/AN/A-967.49%-142.43%-100.84%N/A
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
-$20.25M-$3.01N/AN/AN/A-184.64%-47.29%8/14/2025 (Estimated)

Latest LGVN, FBIO, VTVT, and IPA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
-$0.73-$0.77-$0.04-$0.77N/AN/A
3/31/2025Q4 2024
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
-$0.79-$0.26+$0.53-$0.26$16.30 million$15.12 million
3/28/2025Q3 2025
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
-$0.06-$0.06N/A-$0.46$6.59 million$4.23 million
3/20/2025Q4 2024
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
-$0.87-$0.55+$0.32-$0.55N/A$0.02 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
N/AN/AN/AN/AN/A
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
N/AN/AN/AN/AN/A
Longeveron Inc. stock logo
LGVN
Longeveron
N/AN/AN/AN/AN/A
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
N/A
1.23
1.06
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
0.36
1.01
0.85
Longeveron Inc. stock logo
LGVN
Longeveron
N/A
7.67
7.67
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
N/A
6.69
6.69

Institutional Ownership

CompanyInstitutional Ownership
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
96.51%
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
6.70%
Longeveron Inc. stock logo
LGVN
Longeveron
10.01%
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
17.51%

Insider Ownership

CompanyInsider Ownership
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
33.40%
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
6.83%
Longeveron Inc. stock logo
LGVN
Longeveron
19.12%
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
4.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
17029.57 million18.39 millionOptionable
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
8045.77 million28.94 millionNot Optionable
Longeveron Inc. stock logo
LGVN
Longeveron
2014.93 million12.00 millionNot Optionable
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
93.19 million3.15 millionNot Optionable

Recent News About These Companies

vTv resumes Phase III oral T1D drug study
vTv Therapeutics initiated with a Buy at H.C. Wainwright
vTv Therapeutics reports Q4 EPS (55c) vs ($1.67) last year
vTv Therapeutics stock surges on FDA update

New MarketBeat Followers Over Time

Media Sentiment Over Time

Fortress Biotech stock logo

Fortress Biotech NASDAQ:FBIO

$1.83 +0.05 (+2.81%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$1.83 0.00 (-0.05%)
As of 06:11 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

ImmunoPrecise Antibodies stock logo

ImmunoPrecise Antibodies NASDAQ:IPA

$0.53 -0.02 (-4.15%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$0.54 +0.01 (+1.31%)
As of 05:04 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.

Longeveron stock logo

Longeveron NASDAQ:LGVN

$1.34 -0.01 (-0.74%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$1.37 +0.03 (+2.24%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

vTv Therapeutics stock logo

vTv Therapeutics NASDAQ:VTVT

$16.05 -1.71 (-9.63%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$16.52 +0.47 (+2.96%)
As of 05/27/2025 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.